

KPV Available for Research Use Only

(0.25 mg – 0.5 mg daily, increased to 1 mg to 2 mg daily as needed)

KPV is the C-terminal tripeptide (Lys-Pro-Val) of α -melanocyte-stimulating hormone. It has evidence for reducing intestinal inflammation and neutrophil recruitment and plausible inhibition of NF- κ B and MAPK signaling and support for intestinal epithelial-barrier integrity. [3–5,7,9] Practitioner and community reports describe improvements in gut symptoms and inflammatory discomfort. Practitioner and community reports describe use for gut, skin, and systemic inflammatory symptoms. Broader skin and systemic applications remain plausible. [7,11,12,26]

 Probably safe

★ ★ Probably effective for selected outcomes supported by animal studies.

Disclaimer: These notes are not authoritative and should not be interpreted as definitive scientific guidance. They are summaries, compilations and plausible extrapolations drawn from the most relevant research I was able to locate, and may omit nuances, conflicting data, or emerging evidence. The material reflects an attempt to organize and understand complex topics, not to provide clinical recommendations or expert interpretation.

This document was updated 12-Oct-26. The most recent version of this document is available at <https://pdfs.researcher6076.com/pdfs/kpv.pdf>



KPV's safety assessment rests on preclinical observations. Tolerability findings from animal studies and engineered KPV formulations provide limited reassurance. Long-term human safety remains uncertain. [4–6,9,27]

KPV likely reduces intestinal inflammation, supported by multiple animal colitis studies, with plausible support for mucosal-barrier integrity. Human cell studies support mechanisms involving PepT1-mediated uptake and inhibition of inflammatory signaling. [3–6,9,14,15]

KPV likely reduces neutrophil recruitment, with plausible support for broader anti-inflammatory effects through inhibition of NF- κ B and MAPK signaling and reduced inflammatory mediator production. Community reports describe wider symptom improvements. [3,4,7,11,26]

Dosage & Patterns

There is no evidence-based human dose for KPV. Relying on practitioner and community reports

- **0.25–0.5 mg daily is a reported use pattern.**
- **1–2 mg/day for short courses, such as 3–14 days, is also reported.**
- **Larger doses up to 5 mg/day are occasionally reported, but very much outside mainstream discussions.**

Community reports describe continuous KPV use. Its largely melanocortin-receptor-independent actions provide a plausible rationale for a low risk of classical receptor

KPV Available for Research Use Only

(0.25 mg – 0.5 mg daily, increased to 1 mg to 2 mg daily as needed)

desensitization, but do not establish freedom from tolerance or endocrine effects. Adaptation within inflammatory pathways remains plausible, and long-term human safety remains uncertain. [3–5,7,27]

Benefits

Core anti-inflammatory actions

- **Likely reduction in intestinal inflammatory cytokine activity**, including TNF- α and IL-6, with plausible inhibition of NF- κ B and MAPK signaling. [4,5,7]
- **Plausible suppression of inflammatory signaling** through largely melanocortin-receptor-independent mechanisms. [3,4,7]

Gut and mucosal support

- **Plausible support for intestinal epithelial-barrier integrity** through reduced inflammatory signaling. [4,6,9,15]
- **Likely reduction in intestinal inflammation**. Community reports describe improvements in IBS-like symptoms, food-triggered irritation, and gluten sensitivity. [4,5,26]
- **Plausible support for intestinal mucosal healing**, informed by animal studies of targeted KPV delivery formulations that reduced inflammation and promoted mucosal repair. [6,9,14,15]
- **Likely reduction in inflammation-associated intestinal tumor development**, based on a mouse model of colitis-associated cancer in which protection depended on PepT1-mediated uptake. Broader cancer-protective effects remain plausible. [8]
- **Community reports describe less post-meal discomfort after foods that previously triggered symptoms.**

Skin and tissue calming

- **Likely reduction in localized inflammatory skin swelling**, based on animal findings, with plausible protection against inflammatory skin-cell injury. Practitioner and community reports describe use for eczema, dermatitis, and skin irritation. [11,12,26]
- **Likely support for corneal epithelial wound healing** with topical KPV, based on animal findings. Broader support for wound-healing environments through reduced inflammatory signaling remains plausible. [7,24]

Joint and systemic effects

- **Plausible support for reduced joint inflammation** through anti-inflammatory signaling. Community reports describe relief of overuse soreness and inflammatory joint discomfort. [3,7,26]
- **Plausible support for broader systemic anti-inflammatory effects** through reduced inflammatory signaling. [3,7]
- **Likely attenuation of diet-associated weight gain and adipose-tissue expansion**, based on a mouse study using oral KPV during a high-fat diet. [19]
- **Plausible reduction in hepatic lipid accumulation**, based on a cultured liver-cell study showing reduced lipid buildup under fatty-acid exposure. [18]

KPV Available for Research Use Only

(0.25 mg – 0.5 mg daily, increased to 1 mg to 2 mg daily as needed)

Immune-regulatory effects

- **Plausible reduction in excessive inflammatory signaling** through inhibition of NF-κB and MAPK pathways. [4,7]
- **Plausible antimicrobial activity against *Staphylococcus aureus* and *Candida albicans***, based on laboratory experiments demonstrating inhibited microbial growth or viability. [23]
- Community reports describe stacking KPV with thymic peptides. Complementary effects on inflammatory and immune signaling are plausible.

Reported Practitioner and Community Uses

- **Chronic or recurrent inflammation:** Post-meal inflammatory flares, histamine-related symptoms, low-grade systemic inflammation
- **Gut-related issues:** IBS-like symptoms, food-triggered gut irritation, gluten sensitivity, post-antibiotic gut disruption, “leaky gut”
- **Skin inflammation:** Eczema, dermatitis, psoriasis, inflammatory rashes
- **Joint or soft-tissue inflammation:** Overuse soreness, mild inflammatory joint discomfort, localized swelling after activity
- **Needing immune-regulatory support:** immune systems that “overreact” to triggers, inflammatory flares

Precautions

- **Caution during active, uncontrolled infections:** KPV may reduce inflammatory signs and could mask clinical progression; avoid initiating during severe systemic infections
- **Pregnancy / breastfeeding**

Reported Side Effects

- Fatigue
- Injection-site erythema
- Transient GI upset
- Hypersensitivity reactions have been reported anecdotally; their frequency and causal relationship to KPV remain uncertain.

Drivers of Diminished Response and Mitigation Strategies

KPV’s largely melanocortin-receptor-independent actions provide a plausible rationale for a low risk of classical receptor desensitization. [3,4,7] KPV’s small tripeptide structure provides a plausible rationale for limited immunogenicity. [27] Adaptation within inflammatory pathways and immune homeostasis could plausibly reduce response over time.

Community reports describe continuous KPV use without cycling.

KPV Available for Research Use Only

(0.25 mg – 0.5 mg daily, increased to 1 mg to 2 mg daily as needed)

Biological Mechanism

KPV is the C-terminal tripeptide (Lys-Pro-Val) of α -melanocyte-stimulating hormone. Its anti-inflammatory effects plausibly involve PepT1-mediated uptake into intestinal epithelial and immune cells, followed by inhibition of NF- κ B and MAPK signaling and reduced inflammatory cytokine production. These effects are largely independent of melanocortin-receptor activation. Human bronchial epithelial cell studies also support a plausible mechanism involving inhibition of NF- κ B nuclear entry. [3–5,7] KPV plausibly supports an M2 repair-associated macrophage phenotype; this effect was demonstrated in mice receiving the engineered oral proKPV formulation. [9] KPV likely reduces neutrophil recruitment. [3,5]

KPV plausibly supports intestinal epithelial and mucosal-barrier integrity through reduced inflammatory signaling. In mice with colitis, the engineered oral proKPV formulation restored occludin and ZO-1 expression and reduced intestinal permeability. These findings support a plausible barrier-repair rationale for ordinary KPV. [4,6,9] KPV likely reduces intestinal inflammation, with plausible support for mucosal healing and broader anti-inflammatory applications. [3–7,14,15]

References

1. Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. *Endocr Rev.* 2008;29(5):581-602. <https://doi.org/10.1210/er.2007-0027>
2. Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. *ScientificWorldJournal.* 2010;10:1840-1853. <https://doi.org/10.1100/tsw.2010.173>
3. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. *J Pharmacol Exp Ther.* 2003;306(2):631-637. <https://doi.org/10.1124/jpet.103.051623>
4. Dalmaso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. *Gastroenterology.* 2008;134(1):166-178. <https://doi.org/10.1053/j.gastro.2007.10.026>
5. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. *Inflamm Bowel Dis.* 2008;14(3):324-331. <https://doi.org/10.1002/ibd.20334>
6. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. *Mol Ther.* 2017;25(7):1628-1640. <https://doi.org/10.1016/j.ymthe.2016.11.020>
7. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R

agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73.

<https://pubmed.ncbi.nlm.nih.gov/22837805/>

8. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. <https://doi.org/10.1016/j.jcmgh.2016.01.006>
9. Cheng J, Wu P, Li C, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. 2026;12(3):eaea2989. <https://doi.org/10.1126/sciadv.aea2989>
10. Elliott RJ, Szabo M, Wagner MJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotrophic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122(4):1010-1019. <https://doi.org/10.1111/j.0022-202x.2004.22404.x>
11. Sung J, Ju SY, Park S, et al. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. 2025;95:102837. <https://doi.org/10.1016/j.tice.2025.102837>
12. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284. <https://doi.org/10.1096/fasebj.3.11.2550304>
13. Laroui H, Dalmaso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-53.e1-2. <https://doi.org/10.1053/j.gastro.2009.11.003>
14. Sun J, Xue P, Liu J, et al. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng. 2021;7(10):4859-4869. <https://doi.org/10.1021/acsbiomaterials.1c00792>
15. Zhao Y, Xue P, Lin G, et al. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater. 2022;143:233-252. <https://doi.org/10.1016/j.actbio.2022.02.039>
16. Shao W, Chen R, Lin G, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci. 2021;10(1):227-242. <https://doi.org/10.1039/d1bm01466h>
17. Pawar K, Kolli CS, Rangari VK, et al. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci. 2017;106(7):1814-1820. <https://doi.org/10.1016/j.xphs.2017.03.017>
18. Lee JY, Lee J, Jung WK, et al. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology. 2026;78(3):98. <https://doi.org/10.1007/s10616-026-00967-z>

KPV Available for Research Use Only

(0.25 mg – 0.5 mg daily, increased to 1 mg to 2 mg daily as needed)

19. An SH, Park JY, Lee SJ. KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPAR γ signaling. *Tissue Cell*. 2026;104(Pt 1):103837. <https://doi.org/10.1016/j.tice.2026.103837>
20. Ji HX, Zou YL, Duan JJ, et al. The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against *Candida albicans* vaginitis via inducing macrophage M2 polarization. *PLoS One*. 2013;8(2):e56004. <https://doi.org/10.1371/journal.pone.0056004>
21. Zhang L, Li D, Aierken Y, et al. KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. *Adv Healthc Mater*. 2024;13(32):e2402320. <https://doi.org/10.1002/adhm.202402320>
22. Zhang D, Jiang L, Yu F, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced Colitis. *Front Pharmacol*. 2024;15:1442876. <https://doi.org/10.3389/fphar.2024.1442876>
23. Cutuli M, Cristiani S, Lipton JM, et al. Antimicrobial effects of alpha-MSH peptides. *J Leukoc Biol*. 2000;67(2):233-239. <https://doi.org/10.1002/jlb.67.2.233>
24. Bonfiglio V, Camillieri G, Avitabile T, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. *Exp Eye Res*. 2006;83(6):1366-1372. <https://doi.org/10.1016/j.exer.2006.07.014>
25. Getting SJ, Christian HC, Lam CW, et al. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. *J Immunol*. 2003;170(6):3323-3330. <https://doi.org/10.4049/jimmunol.170.6.3323>
26. Richards A. KPV: The Next Generation Anti-Inflammatory Peptide That Heals from Within: A Scientific Breakthrough in Cellular Repair, Immune Regulation, and Inflammation Control. Biopeptitech. October 20, 2025. Vendor commentary; not peer-reviewed scientific evidence. <https://biopeptitech.com/blogs/news/kpv-the-next-generation-anti-inflammatory-peptide-that-heals-from-within-a-scientific-breakthrough-in-cellular-repair-immune-regulation-and-inflammation-control>
27. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting presentations: KPV-related bulk drug substances. July 23, 2026. <https://www.fda.gov/media/193773/download>